Powering Global Breakthroughs Through Asia’s Biotech Ecosystem
WorldUpstart's Asia Soft Landing Program helps advanced therapeutics companies develop a global strategy that includes Asia's clinical, manufacturing, and financing ecosystem to hit key milestones faster — and de-risk your assets and build a stronger valuation story.
A Faster Path to Global Commercialization
RNA, nucleic acid, cell, and advanced therapy companies are facing a challenging fundraising environment. Timelines are lengthening. Non-dilutive funding is scarcer. And many investors now expect clinical progress and manufacturing validation before committing capital.
The companies that will succeed aren't waiting for conditions to improve. They're finding smarter, more capital-efficient paths to the milestones that move valuation. Increasingly, that path runs through Asia. The region is emerging as a practical opportunity to move faster, extend runway, and strengthen valuation and WorldUpstart’s Asia Soft Landing Program can help you navigate it.
Asia Is a Powerful Opportunity. It's Also Complex to Navigate Alone.
Southeast Asia, and particularly Singapore, Malaysia, and Australia form a powerful regional development triangle — offering efficient clinical pathways, cost-effective GMP manufacturing, grants and investment capital, and mature ecosystems for IP, talent, and regulatory credibility.
But access is everything. The right clinical sites, CDMOs, and investors don't come from a Google search — they come from years of relationship-building on the ground.
That's exactly what WorldUpstart brings. Ranked among the top 10 global accelerators, we've spent years building those relationships so you don't have to. This program gives you direct access to the network, knowledge, and a structured path to turn Asia's opportunity into milestones that move your valuation.
Built for Companies at a Pivotal Inflection Point
This program is designed for founders who are close to a regulatory package, close to the clinic, close to their next round, or close to a manufacturing milestone — and need a smarter, more capital-efficient path to get there. We work with a small, focused cohort so that every introduction and every hour of mentoring is targeted to your situation.
You should apply if you are:
Preparing for first-in-human studies with strong pre-clinical or IND-enabling data and need a credible, cost-efficient pre-clinical, regulatory, or development path
Navigating a fundraising gap and need to advance key milestones before your next round — without burning capital you don't yet have
Targeting U.S., EU, or Asian investors and want to return to that conversation with clinical progress, manufacturing validation, or regional traction behind you
Seeking GMP manufacturing options that are both cost-effective and rigorous enough to satisfy investor due diligence
Working in RNA therapeutics, nucleic acid platforms, mRNA vaccines, gene editing, cell therapy, or advanced biologics — where Asia's infrastructure is most purpose-built for what you're building
Take the Next Step
Applications for the inaugural cohort are now open.
Spots are limited.